Skip to main content
. 2012 May;86(9):5230–5243. doi: 10.1128/JVI.06728-11

Table 1.

Associations between supertype members and polymorphisms in optimal epitopes at a q value of <0.2

Protein Epitope Sequence
Location HLAc Associationsd Supertype(s)e
Optimala Consensusb
Gag KK9 KIRLRPGGK KIRLRPGGK 18–26 A*03:01 A*03:01(R18K, K28X), A*30:01(X20S, C/K28Q), A*31:01(X18Q), A*33:01(X18Q, X28Q), A*74:01(R20K, R28X, Q30X) A3
RLRPGGKKK RLRPGGKKH 20–28
RLRPGGKKKY RLRPGGKKHY 20–29
KW9 KYKLKHIVW HYMLKHLVW 28–36 A*24:02 A*23:01(R28X, L34I), A*24:02(R28X) A24
RY11 RSLYNTVATLY RSLYNTVATLY 76–86 A*30:02, B58, B63 A*01:01(E73K, Y79F/H), A*29:02(L85I), A*29:11(C87X), A*30:02(T81A), A*36:01(Y79H), B*58:02(C87X) A1, A24
LY9 LYNTVATLY LYNTVATLY 78–86 A*29:02, B*44:03 A*01:01(Y79F/H), A*29:02(L85I), A*29:11(C87X), A*30:02(T81A), A*36:01(Y79H) A1, A24
TK8 TLYCVHQK TLYCVHEK 84–91 A*11:01 A*03:01(X91S), A*34:02(K90R), A*68:01(K90X), A*66:03(T81A, A83V), A*74:01(R91K, V94I) A3
IL10 IEIKDTKEAL IEVRDTKEAL 92–101 B*40:01 B*41:01(E93V), B*44:03(X91Q), B*45:01(E93X) B44
VL10 VHQAISPRTL VHQAISPRTL 143–152 B*15:10 B*14:02(V143I, L147I), B*15:10(A146S) B27
IW9 ISPRTLNAW ISPRTLNAW 147–155 B*57:01, B63 B*57:02(A146P, I147L), B*57:03(A146P, I147L/M), B*58:01(X146P), B*58:02(S146X) B58
KF11 KAFSPEVI KAFSPEVI 162–169 B*57:03 B*57:03(X161D, A163G/S, S165K/N), B*58:01(V168X) B58
KAFSPEVIPMF KAFSPEVIPMF 162–172
EL9 EVIPMFSAL EVIPMFTAL 167–175 A*26:01 A*26:01(V168X, T173 M), A*29:02(X173 M) A1
TL9 TPQDLNTML TPQDLNTML 180–188 B*07:02, B*39:10, B*42:01, B*81:01, C*08:02 B*39:10(E177D, T186X), B*42:01(X182T), B*67:01(T190A), C*08:02(X182H), B*81:01(E177D, Q/T182E/G/S, T186S, L188F, T190X, V191I) B7
TPYDINQML TPQDLNTML
TW10 TSTLQEQIGW TSTLQEQIAW 240–249 B*57:01, B*58:01 B*57:02(T242N, X247 M), B*57:03(T242N, I247V), B*58:01(T242N, L243X, X248A) B58
NY10 NPPIPVGDIY NPPIPVGDIY 253–262 B*35:01 B*35:01(D260E), B*39:10(I250 M), B*53:01(X256T, R264X), B*81:01(X252A) B7
QW9 QASQEVKNW QATQDVKNW 308–316 B*53:01, B*57:01 B*53:01(A309X, N315G), B*58:01(S309A, T310S)
Pr DL9 DTVLEEWNL DTVLEEINL 30–38 A*68:02 A*02:02(X39S), A*02:05(X36V) A2
RT AM9 ALVEICTEM ALTAICEEM 33–41 A*02:01 A*02:01(X35I, X36V, X40D), A*02:02(E36A, X41I) A2
TI8 TAFTIPSI TAFTIPSI 128–135 B*51:01 B*51:01(I135T), B*81:01(X134G) B7
KY9 KQNPDIVIY AQNPEIVIY 173–181 A*30:02 A*29:02(178X), A*30:01(E173X), A*36:01(X178V) A1
IL9 IEELRQHLL IEELREHLL 202–210 B*40:01 B*18:01(E207X), B*44:03(E204X, E207K/N) B44
QR9 QIYPGIKVR QIYPGIKVR 269–277 A*03:01 A*03:01(K277R), A*30:01(Q278X), A*33:03(X273R), A*34:02(R275X) A3
IW9 IAMESIVIW IAMESIVIW 375–383 B*58:01 B*15:16(X386V), B*58:01(I375V, X377Q/T, X379A) B58
EY9 ETKLGKAGY ETKIGKAGY 449–457 A*26:01 A*26:01(K451R, M452X), A*29:01(T450N) A1
Nef RM9 RPQVPLRPM RPQVPLRPM 71–79 B*42:01, B*07:02 B*35:01(Y81F), B*81:01(X71T, L76T/V) B7
TPQVPLRPM RPQVPLRPM
QK10 QVPLRPMTYK QVPLRPMTYK 73–82 A*03:01, A*11:01 A*03:01(A83G, X85L), A*33:01(X71K), A*34:02(A83G), A*66:03(V70I), A*68:01(X82Q) A3
RL9 VPLRPMTY VPLRPMTY 74–81 B*35:01, B*07:02 B*35:01(Y81F), B*81:01(X71T, L76T/V) B7
RPMTYKAAL RPMTYKAAF 77–85
PK8 PLRPMTYK PLRPMTYK 75–82 A*11:01 A*03:01(A83G, X85L), A*34:02(A83G), A*68:01(X82Q) A3
KL10 KAAFDLSFFL KAAFDLSFFL 82–91 B*57:03 B*57:02(A83X), B*57:03(A83X), B*58:01(A83G) B58
AK9 AVDLSHFLK AFDLSFFLK 84–92 A*03:01, A*11:01 A*03:01(A83G, X85L), A*34:02(A83G), A*68:01(X82Q) A3
HW9 HTQGYFPDW HTQGFFPDW 116–124 B*57:01 B*57:03(H116N), B*58:01(X116N) B58
TL10 TPGPGVRYPL TPGPGVRYPL 128–137 B*07:02, B*42:01 B*35:01(V133T), B*53:01(V133I) B7
RW8 RYPLTFGW RYPLTFGW 134–141 A*24:02 A*23:01(F143Y), A*24:02(Y135F/L) A24
YY9 YPLTFGWCY YPLTFGWCF 135–143 B*18:01, B*53:01 B*35:01(V133T), B*53:01(V133I) B7
a

Optimally defined epitopes as defined at http://www.hiv.lanl.gov/content/immunology/tables/optimal_ctl_summary.html. Only optimal epitopes that were restricted by least two HLA alleles are shown. Overlapping optimals with published alleles in the same supertype are grouped together.

b

Consensus in the present cohort. Underlining marks differences from published optimal epitope.

c

HLA alleles associated with the epitope as defined in the optimal epitope definitions.

d

HLA alleles that are related to the published alleles via supertype were tested for associations with polymorphisms within or flanking the optimal epitope. Associations are of the form (YposZ), where Y is a residue that is negatively associated with the HLA allele and Z is a residue that is positively associated with the allele. X indicates no association in the positive/negative direction. All associations with a q value of <0.2 are reported.

e

Supertypes that are represented by HLA alleles that are associated with escape.